Tessera Therapeutics Stock
Tessera Therapeutics is an innovative life sciences company focused on pioneering a new biotechnology called Gene Writing™, which aims to revolutionize genetic medicine. Tessera is developing technologies that allow for precise and efficient modifications to the genome, addressing genetic diseases that traditional gene therapy and editing methods cannot effectively treat.
Sign up for SecondMarket™ to view the market and buy or sell Tessera Therapeutics Stock
Buy + SellTessera Therapeutics Funding
Sign up to gain insights into Tessera Therapeutics funding history, including the funding round, time period, and amount raised.
Sign Up to Unlock the Data| Date | Financing Round | Amount | Price per share* | Valuation* |
|---|---|---|---|---|
| Mar 08, 2022 | Series C | 400.00M | ||
| Jan 13, 2021 | Series B | 231.50M | ||
| Jan 13, 2021 | Series A | 5.00M | ||
| Sep 29, 2020 | Series A | 6.60M | ||
| Sep 30, 2019 | Series A | 13.81M |
See Tessera Therapeutics Valuations + Financials
*Sample data + company shown for illustrative purposes only
Gain insights Into Tessera Therapeutics Stock Valuation + Share Prices
View real-time Tape D™ data on Tessera Therapeutics stock including most recent valuation and historical share price information.
Are you an institutional investor or employee shareholder? Sign up to the SecondMarket™ trading platform.
Get Started
Tessera Therapeutics Management Team
Chief Data Officer
Ian McFayden
Chief Medical and Development Officer
David Davidson
Director
Mary Rozenman
Chief Operating Officer
Hari Pujar
Co-founder, Chief Innovation Officer
Jake Rubens
Director
Elliott Sigal
Chief Human Resources Officer
Becky Lillie
Chief Scientific Officer
Michael Holmes
CTO, Cell Therapy
Madhusudan Peshwa
CFO, President
Howard Liang
CEO, Director
Michael Severino
Director
Melissa Moore
Co-founder, Board Chair
Geoffrey von Maltzahn
Director
Noubar Afeyan
Tessera Therapeutics Major Investors
Longevity Fund, The
Hanwha Venture Capital Corporation
Abu Dhabi Investment Authority (ADIA)
Flagship Pioneering
Alaska Permanent Fund (APFC)
Altitude Life Science Ventures
Cormorant Asset Management
Longevity Fund, The
March Capital
Artis Ventures
Softbank Vision Fund 2
Qatar Investment Authority (QIA)
Learn More About Tessera Therapeutics Stock
Buy Tessera Therapeutics Stock
01Tessera Therapeutics stock does not trade on public stock exchanges. Tessera Therapeutics stock is considered a private security and you need to be an accredited investor to trade shares. To invest in Tessera Therapeutics stock you can either buy shares directly through company or work with a secondary trading marketplace like Nasdaq Private Market.
Learn more about the secondary market for private company shares on the investors page.
Sell Tessera Therapeutics Stock
02Tessera Therapeutics Stock does not trade on public stock exchanges. In order to sell Tessera Therapeutics shares you need to work directly with the company or with a secondary trading marketplace like Nasdaq Private Market. NPM has more than a decade of experience helping sell shares on the private market to our network of institutional investors.
Learn more about NPM services for selling privately held stock on the Employee Shareholders page.
Read more about how to sell private company stock on the private secondary market:
Tessera Therapeutics Stock Price
03Tessera Therapeutics does not have a publicly available stock price because it is privately held and not traded on public stock exchanges. Through the Tape D™ database from Nasdaq Private Market, you can view Tessera Therapeutics share price and other valuable private market data.
Read more about secondary market private company stock prices:
Tessera Therapeutics Stock Ticker Symbol
04There is no ticker symbol for Tessera Therapeutics stock because it is a private company. Private companies do not have ticker symbols like public companies, they are identified primarily by using the company ‘street’ name or legal name.
Criteria to Sell Tessera Therapeutics Stock
05Nasdaq Private Market currently works with employees, ex-employees, and other company investors. In order to sell Tessera Therapeutics stock you need to receive the company’s approval, which Nasdaq Private Market manages on your behalf.
Learn more about selling privately held stock on the Employee Shareholders page.
Read more about how to sell shares of a private company and eligibility for selling privately held stock:
Criteria to Buy or Invest in Tessera Therapeutics Stock
06Currently, Nasdaq Private Market only works with accredited entities and institutional investors to purchase private company stock. In order to invest in Tessera Therapeutics stock, you need to be an accredited entity or institutional investor.
Learn more about the Nasdaq Private Market tool kit for investors on the Investor Trading page.
Tessera Therapeutics Stock Settlement
07Once you buy or sell, stock share ownership must transfer before funds are wired. With Nasdaq Private Market, clients leverage our patent-pending Transfer and Settlement technology which streamlines and manages transfer activity from match to settlement.
To learn more about private company stock Transfer and Settlement, check out the Transfer and Settlement page.
Tessera Therapeutics IPO
08Tessera Therapeutics is a private company and has not had an IPO. There is currently no Tessera Therapeutics IPO price. Get started to begin exploring the Nasdaq Private Market Tape D™ database and gain access to actionable data related to Tessera Therapeutics IPO.
Learn more about Tape D™ private company stock data for institutional investors on the on the Tape D™ Product Page.
Sign up for SecondMarket™ to view the market and buy or sell Tessera Therapeutics Stock
Buy + Sell*All trademarks are the property of their respective owner(s). Unless expressly stated otherwise, companies listed on this site are not sponsoring, endorsing, or otherwise affiliated with, Nasdaq Private Market, LLC, and none of the statements on this website should be attributed to a listed company.
